Industry · RWELive engine
Viewing as

Post-market real-world evidence

A myopia-control registry surface for lens manufacturers: axial-length velocity by treatment, the Stellest 1.0 → 2.0 generational step, subgroup performance across a diverse population, and registry governance.

Modelled · synthetic demo cohort · n=3,400 · 28 sites · 24-mo horizon
Cohort
3,400
subjects
Sites
28
contributing
Ethnic groups
6
represented
Visits
9,508
24-mo horizon

The generational step

Modelled
43.2%

lower axial-length velocity, Stellest 2.0 vs 1.0

0.147 mm/yr 0.084 mm/yr mean AL velocity (per-protocol, full-adherence subgroup).

All-comers: 34.3% lower(0.163 mm/yr 0.107 mm/yr)

Basis: per-protocol (full-adherence subgroup). Lower AL velocity = slower myopia progression.

Mean AL velocity

lower is better
Single-visionuncorrected-control baseline0.300 mm/yrStellest 1.0per-protocol0.147 mm/yrStellest 2.0per-protocol0.084 mm/yr0.000.080.160.240.32mm/yr
Per-protocol (full-adherence) subgroup. Single-vision is the fastest-progressing arm; Stellest 2.0 the slowest.

Head-to-head effectiveness

lower is better
Modelled

Current-generation arms on mean 24-month AL velocity. Lower bars = slower axial elongation; Stellest 2.0 leads the cohort.

Stellest 2.0n=4710.107 mm/yrMiyoSmartn=4060.142 mm/yrZeiss MyoCaren=2750.168 mm/yrSingle-visionn=6920.300 mm/yr0.000.080.160.240.32mm/yr

Stellest 2.0 across ethnicities

lower is better
Modelled

AL velocity holds across all six groups — evidence the effect generalises across a diverse population, not just one anchor cohort.

Europeann=1750.086 mm/yrIndigenousn=150.096 mm/yrOthern=340.101 mm/yrSouth Asiann=670.102 mm/yrMiddle Easternn=380.108 mm/yrEast Asiann=1420.139 mm/yr0.000.040.070.110.15mm/yr

Adherence & tolerability

Modelled

Adherence distribution

  • Full adherence73.1% · n=2,485
  • Partial22.4% · n=761
  • Poor4.5% · n=154

Mild photophobia

1.9%

n=66

Discontinuation

1.8%

n=61

Upgrade opportunity

Modelled
766
on Stellest 1.0
123
upgrade candidates (16.1%)

On Stellest 1.0 with inadequate control (ORANGE/RED AL-velocity zone) at 24 months.

Illustrative lens upliftA$320/upgrade
A$39,360

MODELLED — illustrative demo figure, not an observed commercial outcome.

Registry & governance

research pillar
Modelled
3,400
Subjects
28
Sites
9,508
Visits
6
Ethnic groups
100.0%
IMI minimum dataset
+41.0%
12-mo enrolment growth
Retrospective 2,040Prospective 1,360IMI dataset 100.0%

Australian sovereign hosting · de-identified by construction · audit-logged.

Modelled · synthetic demo cohortseed 42ref year 2026live enginegenerated 2026-06-15

Every figure on this page is modelled on a synthetic demo cohort— not an observed clinical or commercial outcome. Effect sizes are derived from the live MyopiAI engine’s L2 baselines and L3 treatment reductions, so the dashboard cannot contradict a live prediction. Baselines sampled from app.layers.l2_norms; natural-history velocity from app.models.trajectory; treatment reductions from app.layers.l3_twin._ARMS + compliance_factor.